You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The agency is providing the material freely and asking for feedback, so it can fix possible problems before more widely disseminating it to labs and companies.
The CRISPR-COVID assay, which is the first CRISPR-based test for SARS-CoV-2 in China, is faster than PCR-based testing, the researchers said.
The company believes the pandemic will accelerate the adoption of its cancer diagnostics as patients and doctors look for faster and more convenient tests.
Caspr's assay can be transported at room temperature and performed without complex external equipment, making it ideal for low-resource environments.
The companies will combine the Binx io diagnostic platform with Sherlock Bio's CRISPR technology to create an easy-to-use rapid test for the point of care.
In a separate study, researchers studying the use of Oncotype DX in African-American men found it to be predictive of disease outcomes regardless of race.
New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.
In a study published last month, Mammoth demonstrated the technology's sensitivity, specificity, and speed compared to PCR-based COVID-19 testing.
Children's Hospital Los Angeles used a SARS-CoV-2 sequencing panel to determine if patients had become infected from the same source as healthcare workers.
The company saw orders for its Cologuard colorectal cancer test fall 63 percent during the first 20 days of April because of a decline in standard healthcare visits.